Organogenesis Holdings Inc. (NASDAQ:ORGO) is reporting third quarter earnings results on Monday 9th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.08 per share.
For the full year, analysts predict revenues of $ 275.12 million, while looking forward to loss of $ 0.39 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 273.00 million ~ $ 277.00 million
Click Here For More Historical Outlooks Of Organogenesis Holdings Inc.
Previous Quarter Performance
Organogenesis Holdings Inc. communicated loss for the second quarter of $ 0.05 per share, from the revenue of $ 68.96 million. The quarterly revenues increased 6.17 percent compared with the same quarter last year. According to street consensus, ORGO was expected to report 2Q20 loss of $ 0.22 per share from revenue of $ 58.83 million. The bottom line results beat street analysts by $ 0.17 or 77.27 percent, at the same time, top line results outshined analysts by $ 10.13 million or 17.22 percent.
Stock Performance
On Friday, shares of Organogenesis Holdings Inc. has traded high as $ 4.09 and has cracked $ 3.86 on the downward trend, reaching $ 4.01 with volume of 83.80 thousand shares.
According to the previous trading day, closing price of $ 4.01, representing a 57.89 % increase from the 52 week low of $ 2.47 and a 53.24 % decrease over the 52 week high of $ 8.34.
The company has a market capital of $ 422.72 million and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
Conference Call
Organogenesis Holdings Inc. will be hosting a conference call at 5:00 PM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website organogenesis.com
Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The companys advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports medicine products comprise ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical applications in targeted soft tissue repairs; and PuraPly AM for the surgical treatment of open wounds.
